Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76,851,274
-
Total 13F shares
-
17,563,087
-
Share change
-
-156,663
-
Total reported value
-
$173,174,992
-
Price per share
-
$9.86
-
Number of holders
-
59
-
Value change
-
-$1,947,261
-
Number of buys
-
26
-
Number of sells
-
21
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2019
As of 30 Jun 2019,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,563,087 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, BVF INC/IL, Vivo Capital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., EVENTIDE ASSET MANAGEMENT, LLC, Capital International Investors, Capital World Investors, Aquilo Capital Management, LLC, Point72 Asset Management, L.P., and ACUTA CAPITAL PARTNERS, LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.